Streetbeat News

Analyst Ratings

NIC

Stephens & Co. analyst Terry McEvoy has downgraded Nicolet Bankshares (NYSE:NIC) from Overweight to Equal-Weight.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 11:06 am

NET

Cloudflare shares are trading lower after a downgrade from Guggenheim from Neutral to Sell. This comes after the stock had gained last week due to strong earnings and guidance.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:05 am

EQBK

Stephens & Co. analyst Terry McEvoy has downgraded Equity Bancshares (NYSE:EQBK) from Overweight to Equal-Weight and set a price target of $30.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 11:05 am

CLVT

B of A Securities analyst Heather Balsky has downgraded Clarivate (NYSE:CLVT) from Neutral to Underperform and lowered the price target from $10 to $6.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 11:04 am

PANW

Barclays analyst Saket Kalia maintains an Overweight rating on Palo Alto Networks (NASDAQ:PANW) and raises the price target from $245 to $275.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:02 am

CGEN

Compugen (NASDAQ:CGEN) reported Q2 losses of $(0.11) per share, beating the analyst consensus estimate of $(0.13) by 15.38 percent. This is unchanged from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:00 am

MNST

Piper Sandler has upgraded Monster Beverage's stock from Neutral to Overweight, leading to a rise in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 10:59 am

GLBE

Benchmark analyst Mark Zgutowicz has initiated coverage on Global E Online (NASDAQ:GLBE) with a Buy rating and a price target of $50.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:59 am

TU

Barclays analyst Kannan Venkateshwar has maintained an Equal-Weight rating on TELUS (NYSE:TU) and lowered the price target from $21 to $20.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 10:57 am

PRTK

HC Wainwright & Co. analyst Ed Arce has reiterated a Neutral rating on Paratek Pharmaceuticals (NASDAQ:PRTK) and maintained a price target of $2.15.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:57 am